Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)
Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)
Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Expanded results from CheckMate 648 of first-line nivolumab + chemotherapy or ipilimumab vs chemotherapy alone in advanced esophageal squamous cell cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.